Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL23AP31 is a processed pseudogene of ribosomal protein L23a, located on human chromosome 2 (GRCh38: CM000664.2, 2:218,841,599-218,842,065) and does not encode a functional protein[4]. Pseudogenes like RPL23AP31 are segments of DNA similar to normal genes but typically non-functional due to mutations, deletions, or the absence of regulatory elements required for gene expression. While some ribosomal protein L23a pseudogenes have shown differential expression and potential association with cancer biology or immune response (e.g., RPL23AP53 in melanoma)[2], RPL23AP31 itself has not been specifically implicated as a functional molecule, biomarker, or therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ribosomal protein L23a pseudogene 31 (RPL23AP31).